ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Validation of the Arabic version of the composite autonomic symptom score 31 questionnaire in diabetic autonomic neuropathy.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic autonomic neuropathy (DAN) is a significant complication of diabetes. The Composite Autonomic Symptom Score-31 (COMPASS-31) is a widely used and validated instrument to assess autonomic dysfunction, yet no validation of its use exists in the Arabic language. In this study, we aimed to develop and validate an Arabic language version of the COMPASS-31 (A-COMPASS-31) in a cohort of Egyptian patients with DAN.
methodsWe enrolled 20 diabetic subjects with DAN and 20 age- and sex-matched diabetic subjects without DAN. Following International Society for Pharmacoeconomics and Outcomes Research (ISPOR)-guided adaptation, the A-COMPASS-31 was developed and subsequently administered twice (four weeks apart) for test-retest reliability. Convergent validity was evaluated against the Ewing battery of autonomic tests, sympathetic skin response (SSR), the neuropathic pain scale (NPS), somatic neuropathy (The Utah Early Neuropathy Scale (UENS)), and quality of life (EuroQol-5 Dimensions-5 Levels (EQ-5D-5 L)) measures. Receiver operating characteristic (ROC) analysis determined diagnostic accuracy.
resultsA-COMPASS-31 demonstrated excellent reliability (Cronbach’s α = 0.841; ICC = 0.992). It significantly correlated with the UENS (rs=0.517, p = 0.001), NPS (rs=0.495, p = 0.001), and EQ-5D-5L (rs=-0.539, p = 0.001). ROC analysis yielded fair diagnostic accuracy (AUC = 0.742, 95% CI 0.580–0.867, p = 0.003) with an optimal cut-off of 28.43 (sensitivity 80%, specificity 65%).
conclusionThe A-COMPASS-31 is a reliable and valid instrument for assessing autonomic symptoms in Arabic-speaking diabetic patients. Its strong correlation with neuropathy severity scales and quality of life measures supports its utility as a first-line clinical screening tool. Due to its modest specificity, initial screening should be followed by objective autonomic testing for definitive diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.